gene therapy industry News
-
Cell and Gene Therapy Industry Comes Together for Matica Bio’s New Global Event
Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, hosted an inaugural event this week, Global Cell & Gene Day, with CHA Medical & Bio Group, providing a specialized venue for learning, innovation and networking for the advancing cell and gene therapy ...
-
Minaris will be the commercial manufacturer in Europe for Skysona™, bluebird bio`s gene therapy for CALD
Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for SkysonaTM (elivaldogene autotemcel, Lenti-D™), a product of bluebird bio, Inc. Today, the European Commission (EC) has granted marketing authorization for SkysonaTM, the ...
-
Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms
Total capital raised of $330 million since the Company’s launch in 2020 Financing expands planned usage of Company’s 20 cGMP suites containing multiple 50L, 500L, 1,000L and 5,000L bioreactors for research-to-commercial gene therapy manufacturing Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it has raised $90 ...
-
GPB Scientific Announces Initial Availability of Advanced Cell Separation Platform; Name Change to Curate Biosciences
GPB Scientific, Inc. has launched its go-to-market activities for the transformational Curate® Cell Processing System to streamline the manufacture of cell therapies, making them economically and reliably available to the largest number of patients. The company's advanced cell separation platform is in evaluations at select biopharmas, contract manufacturers, and academic centers ahead of the ...
-
T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy
BERLIN, GERMANY, and SOMERSET, N.J. – September 21, 2020 — T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, ...
By T-Knife GmbH
-
Biotech Startup Mekonos raises oversubscribed $25 million round to overcome pharma industry’s cell & gene therapy delivery hurdles
Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, ...
-
Virica Biotech Announces Industry Veteran, Beth Thompson-Webb, as Chief Commercial Officer
Virica Biotech Inc. (“Virica”), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be joining the company as Chief Commercial Officer (CCO), effective January 9, 2023. Based out of Boston, MA, Ms. Thompson-Webb will be leading Virica’s commercial efforts to drive global sales and new business growth. ...
-
Pronalyse Unveils Gene Therapy Products Characterization Service to Safely Accelerate Drug Development
Pronalyse is a new division of Creative Proteomics, which is an integrated CRO company with rich experience in providing drug development services. The product manager of the company is excited to launch the Gene Therapy Products Characterization service to help clients overcome the challenges of gene therapy analytical development, which include characterization, quality control, and the need to ...
-
Delivering gene therapy’s promise
The human body consists of trillions of cells, each possessing their own copy of DNA that provides the blueprint for making a human. Despite sharing the same DNA, different cells activate a varied mix of genes within them to enable differentiation into various tissues and organs. For millions of people, unfortunately, some of these genes do not function properly, resulting in diseases and ...
-
AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene ...
By Bayer AG
-
Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros
Strong market uptake of Nubeqa and Kerendia Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention High-value late-stage development portfolio Positive study outcomes from cell & gene therapy pipeline would provide potential upside Shift of resources enhances commercialization and competitiveness Acquired arm’s ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you